- Other backers include Y Combinator, age1, Modi Ventures and Wilson Sonsini
- The funding will be used to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity
- General Proximity was founded in 2019
General Proximity, a San Francisco-based biotech platform, has secured $16 million in seed funding.
Aydin Senkut, founder and managing partner at Felicis, led the round. Other backers include Y Combinator, age1, Modi Ventures and Wilson Sonsini.
The funding will be used to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity.
“It was clear from our first meeting with Armand that General Proximity is going to be one of the technologies that propels us towards cures for cancer and many other diseases,” said Senkut in a statement. “We quickly became convinced that their cutting-edge proximity approach would enable them to solve some of the most ambitious and consequential challenges in drug discovery, paving the way for a bold new era of human healthspan and longevity extension.”
General Proximity was founded in 2019.
Based in Menlo Park, California, Felicis focuses on early-stage investments and currently manages over $3 billion in capital across nine funds.
- Other backers include Y Combinator, age1, Modi Ventures and Wilson Sonsini
- The funding will be used to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity
- General Proximity was founded in 2019
General Proximity, a San Francisco-based biotech platform, has secured $16 million in seed funding.
Aydin Senkut, founder and managing partner at Felicis, led the round. Other backers include Y Combinator, age1, Modi Ventures and Wilson Sonsini.
The funding will be used to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity.
“It was clear from our first meeting with Armand that General Proximity is going to be one of the technologies that propels us towards cures for cancer and many other diseases,” said Senkut in a statement. “We quickly became convinced that their cutting-edge proximity approach would enable them to solve some of the most ambitious and consequential challenges in drug discovery, paving the way for a bold new era of human healthspan and longevity extension.”
General Proximity was founded in 2019.
Based in Menlo Park, California, Felicis focuses on early-stage investments and currently manages over $3 billion in capital across nine funds.
